Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aucta Announced FDA Approval of A Generic Version of Trileptal®(oxcarbazepine) Oral Suspension
Details : Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat parti...
Product Name : Trileptal-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin receives tentative US FDA approval for Oxcarbazepine ER tablets
Details : Oxtellar XR-Generic (oxcarbazepine) is an antiepileptic drug (AED) indicated for the treatment of partial-onset seizures in patients aged six years and older.
Product Name : Oxtellar XR-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2025
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
USFDA Gives Final Nod to Zydus’ Tablets for Treatment of Seizures
Details : Oxcarbazepine tablets produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to tre...
Product Name : Trileptal-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2018
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : National Multiple Sclerosis Society | Novartis Pharmaceuticals Corporation | Barts & The London NHS Trust | University College, London | Royal Free Hospital NHS FT | Mid and South Essex NHS FT | St George's Healthcare NHS Trust | Barnet and Chase Farm Hos
Deal Size : Inapplicable
Deal Type : Inapplicable
Protective Role of Oxcarbazepine in Multiple Sclerosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2014
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : National Multiple Sclerosis Society | Novartis Pharmaceuticals Corporation | Barts & The London NHS Trust | University College, London | Royal Free Hospital NHS FT | Mid and South Essex NHS FT | St George's Healthcare NHS Trust | Barnet and Chase Farm Hos
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2012
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2012
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2010
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Aucta is a global brand that creates better products from proven molecules.
